Efficacy of Lactobacillus reuteri PBS072 and Bifidobacterium breve BB077 in the prevention and treatment of work-related stress symptoms: a cross-over randomized trial

开始日期2021-03-25

申办/合作机构-

NCT04363372 / Withdrawn临床2期

A Pilot, Multiple Dose Study to Evaluate the Efficacy and Safety of MRx-4DP0004 in Hospitalised Patients With Symptoms of COVID-19 (SARS-CoV-2 Infection)

This is a randomised, double-blind, placebo controlled study to evaluate the efficacy and safety of MRx-4DP0004 in patients with COVID-19.
90 hospitalised patients will be enrolled and randomised (2:1) to receive MRx-4DP0004 or placebo for up to 14 days.
MRx-4DP0004 is an immunomodulating Live Biotherapeutic Product (LBP) which is expected to prevent or reduce the hyperinflammatory response to SARS-CoV-2 infection without impairing viral clearance.

开始日期2020-08-01

申办/合作机构

4D Pharma Plc

EUCTR2020-001597-30-GB / Unknown status临床2期

A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection)

开始日期2020-05-29

申办/合作机构

4D Pharma Plc

100 项与 MRx-4DP-0004 相关的临床结果

登录后查看更多信息

100 项与 MRx-4DP-0004 相关的转化医学

登录后查看更多信息

100 项与 MRx-4DP-0004 相关的专利（医药）

登录后查看更多信息

179

项与 MRx-4DP-0004 相关的文献（医药）

2024-01-01·Molecular neurobiology

Bifidobacterium breve Probiotic Compared to Lactobacillus casei Causes a Better Reduction in Demyelination and Oxidative Stress in Cuprizone-Induced Demyelination Model of Rat

Article

作者: Rostami-Mansoor, Sahar ; Ghasemi-Kasman, Maryam ; Hasaniani, Nima ; Halaji, Mehrdad

Despite the anatomical separation, strong evidence suggested a bidirectional association between gut microbiota and central nervous system. Cross-talk between gut microbiota and brain has an important role in the pathophysiology of neurodegenerative disorders and regenerative processes. However, choosing the appropriate probiotics and combination therapy of probiotics to provide a synergistic effect is very crucial. In the present study, we investigated the effect of Lactobacillus casei (L. casei) and Bifidobacterium breve (B. breve) on alternation performance, oxidant/antioxidant biomarkers, the extent of demyelination, and the expression level of HO-1, Nrf-2, Olig2, MBP, PDGFRα, and BDNF in cuprizone (CPZ)-induced demyelination model of rat corpus callosum. In order to induce this model, rats received oral administration of CPZ 0.6% w/w in corn oil for 28 days. Then, L. casei, B. breve, or their combinations were orally administrated for 28 days. Y maze test was performed to investigate the alternation performance. Oxidant/antioxidant biomarkers were determined by colorimetric methods. Extent of demyelination was investigated using FluoroMyelin staining. The genes' expression levels of antioxidant and myelin lineage cells were assessed by quantitative real time PCR. The results showed the probiotics supplementation significantly improve the alternation performance and antioxidant capacity in demyelinated corpus callosum. Interestingly, B. breve supplementation alleviated demyelination and oxidative stress levels more than the administration of L. casei alone or the combination of two probiotics. These observations suggest that B. breve could provide a supplementary strategy for the treatment of multiple sclerosis by increasing antioxidant capacity and remyelination.

2023-12-31·Oncoimmunology

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status

Article

作者: Kovacs, Tamas ; Kalcsevszki, Regina ; Dulka, Edit ; Revisnyei, Peter ; Ligeti, Balazs ; Dora, David ; Krizsán, Dániel ; Megyesfalvi, Zsolt ; Weiss, Glen J ; Dome, Balazs ; Lohinai, Zoltan ; Galffy, Gabriella

Due to the high variance in response rates concerning anti-PD1 immunotherapy (IT), there is an unmet need to discover innovative biomarkers to predict immune checkpoint inhibitor (ICI)-efficacy. Our study included 62 Caucasian advanced-stage non-small cell lung cancer (NSCLC) patients treated with anti-PD1 ICI. Gut bacterial signatures were evaluated by metagenomic sequencing and correlated with progression-free survival (PFS), PD-L1 expression and other clinicopathological parameters. We confirmed the predictive role of PFS-related key bacteria with multivariate statistical models (Lasso- and Cox-regression) and validated on an additional patient cohort (n = 60). We find that alpha-diversity showed no significant difference in any comparison. However, there was a significant difference in beta-diversity between patients with long- (>6 months) vs. short (≤6 months) PFS and between chemotherapy (CHT)-treated vs. CHT-naive cases. Short PFS was associated with increased abundance of Firmicutes (F) and Actinobacteria phyla, whereas elevated abundance of Euryarchaeota was specific for low PD-L1 expression. F/Bacteroides (F/B) ratio was significantly increased in patients with short PFS. Multivariate analysis revealed an association between Alistipes shahii, Alistipes finegoldii, Barnesiella visceriola, and long PFS. In contrast, Streptococcus salivarius, Streptococcus vestibularis, and Bifidobacterium breve were associated with short PFS. Using Random Forest machine learning approach, we find that taxonomic profiles performed superiorly in predicting PFS (AUC = 0.74), while metabolic pathways including Amino Acid Synthesis and Fermentation were better predictors of PD-L1 expression (AUC = 0.87). We conclude that specific metagenomic features of the gut microbiome, including bacterial taxonomy and metabolic pathways might be suggestive of ICI efficacy and PD-L1 expression in NSCLC patients.

2023-11-01·Cellular immunology

Immunomodulatory action of synbiotic comprising of newly isolated lactic acid producing bacterial strains against allergic asthma in mice

Article

作者: Bishnoi, Mahendra ; Kiran Kondepudi, Kanthi ; Naura, Amarjit S ; Sharma, Shikha ; Bhatia, Ruchika ; Monga, Naina

Given the reported role of gut-microbiota in asthma pathogenesis, the present work was carried to evaluate immunomodulatory action of newly isolated lactic acid producing bacterial strains Bifidobacterium breve Bif11 and Lactiplantibacillus plantarum LAB31 against asthma using ovalbumin (OVA) based mouse model. Our results show that both strains modulate Th2 immune response potentially through production of short chain fatty acids (SCFAs), resulting in suppression of OVA-induced airway inflammation. Furthermore, synbiotic comprising of both strains and prebiotic, Isomaltooligosaccharide exhibited superior potential in amelioration of OVA-induced airway inflammation through improved modulation of Th2 immune response. Further, synbiotic protects against OVA-induced mucus hyper-production and airway-hyperresponsiveness. Such protection was associated with normalization of gut microbiome and enhanced production of SCFAs in cecum which correlates closely with population of T-regulatory cells in spleen. Overall, our novel synbiotic possesses the ability to fine-tune the immune response for providing protection against allergic asthma.

项与 MRx-4DP-0004 相关的新闻（医药）

2023-03-02

·PRNewswire

Propulsion of Asthma Pipeline as Novel and Extensive 95+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

Asthma is a chronic disease that affects a substantial number of patients worldwide, including children, a number of pharmaceutical companies are involved in developing drugs for asthma. This involvement includes the development of novel therapies that being evaluated in different phases of development. LAS VEGAS, March 2, 2023 /PRNewswire/ -- DelveInsight's ' Asthma Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the asthma pipeline domain. Key Takeaways from the Asthma Pipeline Report DelveInsight's asthma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for asthma treatment. Key asthma companies such as Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others are evaluating new asthma drugs to improve the treatment landscape. Promising asthma pipeline therapies in various stages of development include CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others. In February 2023, UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development. Dexpramipexole is beig developed by Areteia Therapeutics to inhibit the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. In February 2023, Pulmatrix, Inc. announced that the first patient dosed in a Phase IIb trial evaluating safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. PUR1900 is the company's iSPERSE-enabled dry powder formulation of itraconazole, developed for inhaled pulmonary delivery. The Phase II trial is designed as a randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and duration of treatment with itraconazole, administered as a dry powder for inhalation (PUR1900). Endpoints include safety, tolerability, and potential efficacy outcomes in adult patients with asthma and ABPA. Olatec Therapeutics LLC in February 2023 completed the $40 million Series A round financing, the final closing of which was led by Sanders Morris Harris ("SMH"). Participation in the round came from both existing investors as well as new investors identified by each of Sanders Morris Harris, Advection Growth Capital, and the Company. Proceeds will be principally used to advance Olatec's lead compound, dapansutrile, into later-stage clinical development. Dapansutrile has also been observed to have anti-inflammatory properties and other promising activity in a broad spectrum of over 20 preclinical animal models, including arthritis, asthma, acute myocardial infarction (AMI), heart failure, contact dermatitis, multiple sclerosis, melanoma, pancreatic and breast cancers, spinal cord injury (SCI), Parkinson's and Alzheimer's disease. In January 2023, Avillion LLP, announced that the US Food and Drug Administration (FDA) approved AstraZeneca's Airsupra (albuterol/budesonide, formerly known as PT027) for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS). Upstream Bio, in August 2022, initiated a Phase Ib multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient. UPB-101 is a monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation. TSLP is a cytokine and a key driver of inflammatory response in asthma and other allergic and inflammatory diseases. Request a sample and discover the recent advances in asthma drug treatment @ Asthma Pipeline Report The asthma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage asthma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the asthma clinical trial landscape. Asthma Overview Asthma is a chronic disease of the airways. Asthma is characterized by airway inflammation and spasm. Airways are tubes that transport air into and out of the lungs. Asthmatics cause the inside walls of the airways to become sore and swollen. Because of inflammation and tightening of the muscles surrounding the small airways, the airways in the lungs become narrow. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness. Asthma symptoms differ from person to person. A person may have infrequent asthma attacks, have symptoms only when exercising, or have symptoms all of the time. Asthma symptoms are similar to those of many respiratory infections. A careful clinical history is the first step in asthma diagnosis; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on quality of life. Find out more about drugs for asthma @ New Asthma Drugs A snapshot of the Asthma Pipeline Drugs mentioned in the report: Learn more about the emerging asthma pipeline therapies @ Asthma Clinical Trials Asthma Therapeutics Assessment The asthma pipeline report proffers an integral view of asthma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Asthma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Immunomodulators, Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists, Interleukin 5 receptor antagonists, Matrix metalloproteinase 12 inhibitors, Aldehyde inhibitors, Bacteria replacements; Microbiome modulators, Thymic stromal lymphopoietin inhibitors; Thymic stromal lymphopoietin modulators, Interleukin-33 inhibitors, Inflammasome inhibitors; Interleukin 1 beta inhibitors; Interleukin 18 inhibitors; Interleukin inhibitors; NLRP3 protein inhibitors, Interleukin-17 inhibitors Key Asthma Companies: Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others. Key Asthma Pipeline Therapies: CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others. Dive deep into rich insights for new drugs for asthma treatment; visit @ Asthma Medications Table of Contents For further information on the asthma pipeline therapeutics, reach out @ Asthma Drug Treatment Related Reports Severe Asthma Market Severe Asthma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key severe asthma companies, including AstraZeneca, Novartis, Sanofi, among others. Asthma Pipeline Asthma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key asthma companies, including GSK, AstraZeneca, Teva Pharmaceuticals, among others. Severe Asthma Pipeline Severe Asthma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key severe asthma companies, including AstraZeneca, Novartis, Sanofi, among others. Chronic Obstructive Pulmonary Disease Epidemiology Forecast Chronic Obstructive Pulmonary Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the chronic obstructive pulmonary disease epidemiology trends. Chronic Obstructive Pulmonary Disease Market Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma, among others. Acute Respiratory Distress Syndrome Pipeline Acute Respiratory Distress Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key acute respiratory distress syndrome companies, including Bayer, Faron Pharmaceuticals, BioMarck Pharmaceuticals, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Blogs Emerging Therapies for Severe Asthma Treatment COPD Treatment Market COPD Epidemiological Trends Chronic Respiratory Disease Market Promising Therapies in the ARDS Market Rising Acute Respiratory Distress Syndrome Prevalence ARDS Market Outlook Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

临床2期上市批准临床3期临床1期

2022-11-10

·生物谷

肠好，脑子才好！中国科学家最新发现：这种不起眼的益生菌竟能改变帕金森疾病走向？

有句俗话说的好：“屁股决定脑袋”，简单来说，就是人们所处的“位置”决定了“怎么想，怎么做”。可能大家要说了，这仅仅是一句生活谚语，作为最高统帅的大脑，怎么会任由其他器官挑战权威？从生物学和医学的角度来看，屁股确实不可能，但肠道可以！这就是科研届目前很火的研究方向：微生物群-肠-脑轴（microbiota-gut-brain axis，MGBA），即肠道菌群可能通过神经、免疫和内分泌等途径影响大脑功能和行为。帕金森病（Parkinson’s disease，PD）是一种常见的神经系统变性疾病，已有研究表明，PD的主要原因之一是肠道菌群失衡，益生菌制剂可能对其有治疗作用，但其中的机制和途径尚不清楚。近日，来自我国的田丰伟团队在营养学知名杂志发表了一篇题为“Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease”的研究论文，证明了益生菌B. breve CCFM1067可以通过调节MGBA来预防或治疗PD，或许在未来可以用作PD治疗的口服补充剂。Doi：https://www.mdpi.com/2072-6643/14/21/4678研究者选取40只6周龄雄性C57BL/6小鼠，随机分为四组，每组10只：对照组、MPTP组、L-DOPA组和B. breve CCFM1067组。需要说明的是，MPTP是1-甲基-4-苯基-1，2，3，6-四氢吡啶的简称，可用于实验动物帕金森疾病模型的构建；L-DOPA是左旋多巴的简称，为多巴胺（DA）的前体药物，目前认为可改善帕金森病症状；B. breve CCFM1067为短双歧杆菌的一种。实验共计41天，在第33-37天，除对照组外，对其他组小鼠每日进行MPTP干预，另外L-DOPA组小鼠于第33 ~ 41天口服L-DOPA；B. breve CCFM1067组小鼠于8 ~ 41 天口服B. breve CCFM1067。所有小鼠均称重、每周收集粪便，并进行行为学测试、mRNA表达等进一步实验。本研究共进行了四项行为学试验测试小鼠运动功能，分别为爬杆试验（Pole Test,PT）、狭窄平衡木试验（narrow-beam test,NBT）、转棒疲劳试验（rotarod test,RTR）、旷场试验（open field test,OFT）。结果显示，与对照组相比，MPTP组小鼠表现出明显的运动障碍，运动敏捷性、平衡性、协调性均有所下降，而B. breve CCFM1067治疗可显著减缓解MPTP诱导的运动障碍。短双歧杆菌CCFM1067可减轻MPTP诱导的小鼠运动功能障碍大脑中的多巴胺（Dopamine，DA）与谷氨酸系统协同工作，控制身体的运动和认知功能。DA的合成受到限速酶酪氨酸羟化酶（Tyrosine hydroxylase，TH）的影响，当TH水平低于特定阈值时，PD的运动症状就会出现。组织病理学染色结果发现，B. breve CCFM1067的摄入有效抑制了黑质（Substantia nigra，SN）中TH表达水平的降低，与此同时，PD小鼠纹状体中DA、DOPAC和5-HT等神经递质水平显著提高，神经营养因子BDNF和GDNF的表达有所恢复，提示B. breve CCFM1067可减轻MPTP引起的神经病理改变和神经胶质激活，对PD小鼠具有神经保护作用，这一发现一定程度上解释了小鼠行为改善的内在原因。B. breve CCFM1067可减轻MPTP诱导的神经病理改变和胶质激活那么问题来了，B. breve CCFM1067在PD小鼠中发挥神经保护作用的可能机制是什么呢？除上文所提到的神经营养因子外，活性氧和炎症反应也是PD发展的关键因素。结果表明，通过B. breve CCFM1067治疗，增强了中枢神经系统的抗氧化能力，提示B. breve CCFM1067有助于帮助PD小鼠降低过氧化物的毒性，缓解氧化应激。另外，研究发现，B. breve CCFM1067抑制了PD小鼠的促炎基因表达和蛋白表达，减少了大脑和肠道炎症，增强了抗炎能力，并且值得指出的是，短链脂肪酸的增加可能是B. breve CCFM1067对PD小鼠肠道或大脑具有抗炎作用的原因之一。接下来，研究者检测了三种关键细胞因子（TNF-α、IL-1β和IL-6）在小鼠纹状体和结肠中的mRNA表达，数据表明，肠道菌群失调导致的肠屏障破坏导致促炎细胞因子泄漏，进而导致全身炎症。然而，B. breve CCFM1067治疗可减少肠道炎症，防止PD的发展，这是通过改善肠道屏障的健康，防止炎症分子泄漏，并减少PD小鼠大脑中的炎症来实现的。粪便菌群分析结果表明，B. breve CCFM1067干预可作用于MPTP诱导的肠道菌群微生态失衡，抑制PD小鼠致病菌（志贺氏菌）数量，同时增加有益菌（双歧杆菌和阿克曼氏菌）的数量，即B. breve CCFM1067的保护作用可能是通过恢复正常菌群介导的，同时侧面强调了微生物群失调在PD进展中的重要性。B. breve CCFM1067治疗对MPTP诱导的PD小鼠肠道微生物功能的影响，可能是通过微生物代谢产物介导的综上所述，本研究表明，益生菌B. breve CCFM1067对MPTP诱导的 PD小鼠模型的多巴胺能神经元具有神经保护作用，能改善MPTP引起的小鼠运动障碍、多巴胺能神经元死亡和神经递质减少。其在PD小鼠中发挥神经保护作用的可能机制是通过增加神经营养因子和短链脂肪酸水平，降低神经胶质过度激活、抗氧化应激损伤、炎症反应和肠道菌群失调。希望未来的某一天，益生菌能够真正成为预防和治疗帕金森疾病的有效辅助手段！参考文献：Tiantian Li, Chuanqi Chu, Leilei Yu, et al. Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease. Nutuients. 2022, 14, 4678.撰稿 | 青叶编辑 | cici精彩推荐：1、AI妙用，告别头秃不是梦！我国科学家成功研发头发再生新疗法2、吃的晚减肥难！哈佛医学院最新研究：过晚进食饥饿概率增加20%更易胖！3、万万没想到！影响女性升职加薪的原因竟然还有这件事！4、喝的越多越危险!154万人数据研究显示：中重度饮酒年轻人中风风险增加28%！多少才算适量饮酒？

2022-08-02

·Science Daily

Why breast-fed premature infants have a healthier gut than formula-fed ones

New research found it is not just the content of breastmilk that makes the difference. It is also the way the babies digest it. Human breastmilk has long been considered "liquid gold" among clinicians treating premature infants in a newborn intensive care unit (NICU). Breastmilk-fed "preemies" are healthier, on average, than those fed formula. Why is that true, however, has remained a mystery. New research from the University of Maryland School of Medicine's (UMSOM) Institute for Genome Sciences (IGS), published online in the journal mBio in June found it is not just the content of breastmilk that makes the difference. It is also the way the babies digest it. The research, led by Bing Ma, PhD, Assistant Professor of Microbiology and Immunology at UMSOM and a researcher at IGS, discovered a strain of the Bifidobacterium breve bacteria or B. breve in the gut of breastfed babies who received higher volumes of breastmilk than their counterparts. Those preemies had better nutrient absorption because they developed an intact intestinal wall, one week after birth. B. breve was much less prevalent in both formula-fed babies and breastfed babies with "leaky gut." Babies with leaky gut do not develop a barrier to protect against bacteria and digested food from getting into the bloodstream. For the first time, the team also found that the way B. breve metabolizes breastmilk keeps breastfed babies healthier and allows them to gain weight by strengthening their underdeveloped intestinal barrier. An immature or "leaky" gut can lead to necrotizing enterocolitis (NEC), which is the third leading cause of newborn death in United States and worldwide. In fact, NEC impacts up to 10 percent of premature babies with a devasting mortality rate as high as 50 percent. "Our discovery could lead to promising and practical clinical interventions to strengthen the babies' gut and, therefore, increase survival rates of the most vulnerable preemies," said Dr. Ma. Bifidobacterium in the gut or microbiome has long been known to have health benefits. It includes a diverse set of strains that have very different properties. Some strains are only found in adults; some are mostly in adolescence. One strain, Bifidobacterium infantis, has been seen predominantly in full-term infants. The researchers followed 113 premature babies who were born between 24 and 32 weeks' gestation. This study found Bifidobacterium breve (B. breve) only in preemies who had improved gut barrier function within one week after birth. Dr. Ma and her colleagues discovered that Bifidobacterium breve is genetically equipped to digest nutrients within the cell membrane rather than the more typical external digestion process in which bacteria secrete digestive enzymes onto nutrients to break them down. At the most basic level, the gut microbiome in these breastfed preemies with more B. breve metabolizes carbohydrates differently than it does formula. The researchers say they hypothesize that this process of metabolism then strengthens and matures the intestinal barrier faster, protecting fragile newborns from disease. "We now know that it is not the breastmilk alone that helps preemies develop their intestinal barrier faster," Dr. Ma said. "We will need to find the best way to prophylactically administer B. breve early in life, rather than rely on transmission from breastmilk or even the mother's gut or vaginal microbiota during the birthing process. This is especially critical in formula-fed preemies." Dr. Ma said that more studies are needed to determine if the B. breve originated in the breastmilk, gut, mother's vagina, or even environment. E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, University of Maryland, Baltimore, the John Z. and Akiko K. Bowers Distinguished Professor, and Dean at UMSOM said, "This research can have a far-reaching impact globally. It could ultimately save thousands of premature babies from permanent disability or death associated with an immature and permeable intestine that allows deadly bacteria in." Authors from the Institute for Genome Sciences include Dr. Ma; Michael France, PhD, Post-Doc Fellow; Elias McComb, BS, Research Technician; Lindsay Rutt, MS, Laboratory Research Manager; Pawal Gajer, PhD, Research Associate, Microbiology and Immunology; Li Fu, BS, Laboratory Research Specialist; Hongqiu Yang, PhD, Microbiome Service Laboratory; Mike Humphrys, MS, Microbiome Service Laboratory Director; Luke J. Tallon, BA, Executive Scientific Director, Maryland Genomics; Lisa Sadzewicz, PhD, Executive Director, Maryland Genomics Administration; and Jacques Ravel, PhD, Professor of Microbiology and Immunology, Associate Director, Genomics, and Interim Director, IGS. Authors from other departments within the University of Maryland School of Medicine include Sripriya Sundararajan, MBBS, MD, Associate Professor of Pediatrics and Neonatal Director of OB-MFM Relations; Gita Nadimpalli, MD, PhD, MPH, Graduate Research Assistant; Jose M. Lemme-Dumit, PhD, Post-Doc Fellow, Pediatrics; Elise Janofsky, Pediatrics; Lisa S. Roskes, MD, Pediatrics; Marcela F. Pasetti, PhD, Professor of Pediatrics, Microbiology and Immunology; and Rose M. Viscardi, MD, Professor Emeritus of Pediatrics and Medicine. This study was supported in part by a Gerber Foundation 2018 award (project identifier 6361), the National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (grant number R21DK123674), and the Institute for Clinical and Translational Research (ICTR) at the University of Maryland Accelerated Translational Incubator Pilot (ATIP) award.

100 项与 MRx-4DP-0004 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15751

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	英国	4D Pharma Plc	2020-08-01
哮喘	临床1期	美国	4D Pharma Plc	2019-07-04
哮喘	临床1期	英国	4D Pharma Plc	2019-07-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03851250 (BusinessWire) 人工标引	临床1/2期	哮喘	34	MRx-4DP0004	願範餘鏇憲獵製選鏇艱(鏇鏇網廠範鹽壓網鬱艱) = 淵遞鑰淵選顧蓋構遞憲選衊糧膚艱糧願觸獵築 (鑰廠鏇築鑰膚醖製壓築 ) 更多	积极	2022-01-27
				Placebo	願範餘鏇憲獵製選鏇艱(鏇鏇網廠範鹽壓網鬱艱) = 鹹繭蓋壓鏇醖網鹹鬱築選衊糧膚艱糧願觸獵築 (鑰廠鏇築鑰膚醖製壓築 ) 更多